AROLDI, ANDREA
AROLDI, ANDREA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis
2014 Elli, E; Belotti, A; Aroldi, A; Parma, M; Pioltelli, P; Pogliani, E
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy
2016 Aroldi, A; Cecchetti, C; Colombo, A; Cattaneo, L; Pioltelli, P; Pogliani, E; Elli, E
Chronic myeloid leukemia: Second-line drugs of choice
2016 GAMBACORTI PASSERINI, C; Aroldi, A; Cordani, N; Piazza, R
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
2018 Renso, R; Aroldi, A; Pioltelli, P; Gambacorti-Passerini, C; Elli, E
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients
2019 Fontana, D; Ramazzotti, D; Aroldi, A; Niro, A; Massimino, L; Rea, D; Stagno, F; Martino, B; Campiotti, L; Caocci, G; Elli, E; Fumagalli, M; Ciceri, F; Piazza, R; GAMBACORTI PASSERINI, C
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study)
2019 Elli, E; Iurlo, A; Aroldi, A; Caramella, M; Malato, S; Casartelli, E; Maffioli, M; Gardellini, A; Carraro, M; D'Adda, M; Polverelli, N; Rossi, M; Orofino, N; Carrer, A; Gambacorti-Passerini, C; Antolini, L; Passamonti, F
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors
2019 Andriani, A; Elli, E; Trape, G; Villiva, N; Fianchi, L; Di Veroli, A; Niscola, P; Centra, A; Anaclerico, B; Montanaro, G; Martini, V; Aroldi, A; Carmosino, I; Voso, M; Breccia, M; Montanaro, M; Foa, R; Latagliata, R
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia
2020 Fontana, D; Ramazzotti, D; Aroldi, A; Redaelli, S; Magistroni, V; Pirola, A; Niro, A; Massimino, L; Mastini, C; Brambilla, V; Bombelli, S; Bungaro, S; Morotti, A; Rea, D; Stagno, F; Martino, B; Campiotti, L; Caocci, G; Usala, E; Merli, M; Onida, F; Bregni, M; Elli, E; Fumagalli, M; Ciceri, F; Perego, R; Pagni, F; Mologni, L; Piazza, R; Gambacorti-Passerini, C
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy
2020 Bossi, E; Aroldi, A; Brioschi, F; Steidl, C; Baretta, S; Renso, R; Verga, L; Fontana, D; Sharma, G; Mologni, L; Mussolin, L; Piazza, R; Gambacorti Passerini, C
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
2021 Aroldi, A; Chiarle, R; Gambacorti Passerini, C
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies
2021 Gambacorti Passerini, C; Ruggeri, M; Aroldi, A; Piazza, R; Mazzi, A; De Silvestro, G; Krampera, M; Lanza, F
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706)
2022 Bossi, E; Aroldi, A; Borin, L; Verga, L; Fontana, D; Cocito, F; Manghisi, B; Rindone, G; Cavalca, F; Ripamonti, A; Raggi, M; Malandrin, S; Cavallero, A; Antolini, L; Bonardi, D; Piazza, R; Gambacorti-Passerini, C
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
2022 Gambacorti-Passerini, C; Nicolini, F; Larson, R; Aroldi, A; Fontana, D; Piazza, R; le Coutre, P; Antolini, L; Assouline, S
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
2022 Inzoli, E; Aroldi, A; Piazza, R; Gambacorti Passerini, C
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience
2022 Steidl, C; Aroldi, A; Mologni, L; Crespiatico, I; Fontana, D; Mastini, C; Fumagalli, M; Perfetti, P; Borin, L; Valentini, C; Piazza, R; Gambacorti-Passerini, C
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples
2023 Aroldi, A; Angaroni, F; D’Aliberti, D; Spinelli, S; Crespiatico, I; Crippa, V; Piazza, R; Graudenzi, A; Ramazzotti, D
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients
2023 Fontana, D; Crespiatico, I; Crippa, V; Malighetti, F; Villa, M; Angaroni, F; De Sano, L; Aroldi, A; Antoniotti, M; Caravagna, G; Piazza, R; Graudenzi, A; Mologni, L; Ramazzotti, D
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia
2023 Aroldi, A; Mauri, M; Ramazzotti, D; Villa, M; Malighetti, F; Crippa, V; Cocito, F; Borella, C; Bossi, E; Steidl, C; Scollo, C; Voena, C; Chiarle, R; Mologni, L; Piazza, R; Gambacorti Passerini, C
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making
2023 Civettini, I; Zappaterra, A; Granelli, B; Rindone, G; Aroldi, A; Bonfanti, S; Colombo, F; Fedele, M; Grillo, G; Parma, M; Perfetti, P; Terruzzi, E; Gambacorti-Passerini, C; Ramazzotti, D; Cavalca, F
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas
2023 Rindone, G; Aroldi, A; Bossi, E; Verga, L; Zambrotta, G; Tarantino, S; Piazza, R; Mussolin, L; Chiarle, R; Gambacorti-Passerini, C